Ceragem: "Celtron Circulation Chair Increases Blood Flow in the Back of the Hand by 8% After 30 Minutes of Use"

Ceragem has confirmed the effectiveness and safety of its 'Celtron Circulation Chair,' a medical device designed to improve blood circulation, through clinical research.

Ceragem 'Celltrion Circulation Chair' product image. Ceragem

On August 7, Ceragem announced that following a single 30-minute use of the Celtron Circulation Chair, blood flow on the back of the hand increased by 8.01% compared to before its use.

This study was conducted by Ceragem Clinical, Ceragem's clinical research institution, to objectively verify the actual efficacy of the product with concrete data.

The clinical trial involved 40 adults aged between 19 and 65. After using the circulation mode of the Celtron Circulation Chair once for 30 minutes, researchers compared blood flow in the back of the hand before and after use. As a result, the primary endpoint—blood flow in the back of the hand—increased by 8.01% compared to baseline, demonstrating a statistically significant improvement.

The Celtron Circulation Chair is a chair-type medical device for improving blood circulation, utilizing Ceragem’s electrostatic technology. It has obtained certification from the Ministry of Food and Drug Safety for two proven benefits: improving blood circulation and relieving muscle pain. It is notable for allowing users to manage blood circulation and relieve muscle pain while seated.

Ceragem has continued to accumulate data on the product’s efficacy and safety through ongoing clinical research and human application studies since its launch. The company plans to further strengthen its data-driven research and development system moving forward.

A Ceragem representative said, “The Celtron Circulation Chair is a Ministry of Food and Drug Safety-certified medical device, and this clinical trial demonstrated positive changes in key blood circulation indicators even after a single use. We will continue to validate the product’s effectiveness and safety based on our medical device technology and R&D capabilities, further enhancing reliability.”

This content was produced with the assistance of AI translation services.